Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu-Trantien, … , Denis Larsimont, Karen Willard-Gallo
Chunyan Gu-Trantien, … , Denis Larsimont, Karen Willard-Gallo
Published June 2, 2017
Citation Information: JCI Insight. 2017;2(11):e91487. https://doi.org/10.1172/jci.insight.91487.
View: Text | PDF
Research Article Immunology Oncology

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer

  • Text
  • PDF
Abstract

T follicular helper cells (TFH cells) are important regulators of antigen-specific B cell responses. The B cell chemoattractant CXCL13 has recently been linked with TFH cell infiltration and improved survival in human cancer. Although human TFH cells can produce CXCL13, their immune functions are currently unknown. This study presents data from human breast cancer, advocating a role for tumor-infiltrating CXCL13-producing (CXCR5–) TFH cells, here named TFHX13 cells, in promoting local memory B cell differentiation. TFHX13 cells potentially trigger tertiary lymphoid structure formation and thereby generate germinal center B cell responses at the tumor site. Follicular DCs are not potent CXCL13 producers in breast tumor tissues. We used the TFH cell markers PD-1 and ICOS to identify distinct effector and regulatory CD4+ T cell subpopulations in breast tumors. TFHX13 cells are an important component of the PD-1hiICOSint effector subpopulation and coexpanded with PD-1intICOShiFOXP3hi Tregs. IL2 deprivation induces CXCL13 expression in vitro with a synergistic effect from TGFβ1, providing insight into TFHX13 cell differentiation in response to Treg accumulation, similar to conventional TFH cell responses. Our data suggest that human TFHX13 cell differentiation may be a key factor in converting Treg-mediated immune suppression to de novo activation of adaptive antitumor humoral responses in the chronic inflammatory breast cancer microenvironment.

Authors

Chunyan Gu-Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Grégory Noël, Vu Luan Dang Chi, Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont, Karen Willard-Gallo

×

Figure 6

TFHX13 tumor-infiltrating lymphocytes (TIL) in human breast cancer (BC) are correlated with specific B-TIL maturation stages.

Options: View larger image (or click on image) Download as PowerPoint
TFHX13 tumor-infiltrating lymphocytes (TIL) in human breast cancer (BC) ...
(A–H) Flow cytometric analyses. (A) CXCR5 expression in specific lymphocyte subpopulations from patient peripheral blood (P-PB) and BC (n = range 16–27 BC). One-way ANOVA followed by Tukey’s test. (A–D) Gating strategies are shown in Supplemental Figure 6A; $B cells were analyzed in the total cell gate. (B) Correlation between the number of CXCR5+ cells in specific TIL subpopulations and total CXCL13+ TIL in fresh BC homogenates. (C) Germinal center (GC) TFH (PD-1hiCXCR5hi) or TFHX13 (CXCL13+CD4+; red) cells in tonsils and BC (dot plots); correlation between #GC TFH and #TFHX13 BC TIL (graph). (D) Equally high TFHX13 TIL responses (left) but distinct proliferating (Ki67+) B-TIL subpopulations (middle and right) in 2 BC. B cell differentiation markers are shown for total CD19+ (green) and Ki67+CD19+ (blue) B-TIL (GC B cells = CD38+IgD–; plasmablasts/plasma cells [PC] = CD38hiIgD– or CD38hiCD27int/hi; CD27 = memory B cell marker). (E) Correlation between #GC TFH and #TFHX13 TIL defined in C and #B-TIL subpopulations defined in D. (F) Correlation between % memory cells (excluding PC) in Ki67+ B-TIL (lymphocyte gate) and PC in Ki67+ total B-TIL (total cell gate) from 4 BC with sufficient numbers of Ki67+ B-TIL (gating strategies in Supplemental Figure 6B). (G) PD-1/ICOS–defined CD4+ T cell subpopulations from tonsils. (H) CD45RA and CXCR5 expression on PD-1loICOSloCD4+ T cells from tonsils and BC. (I) Expression of PDCD1 (PD-1), CXCL13, and IL21 genes (qPCR) in CD4+ T cell subpopulations sorted from 5 tonsils. One-way ANOVA followed by Sidak’s test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts